Lawitz 2011b

Methods	Randomised clinical trial
Participants	252 participants Sex: 151 men, 101 women Countries: USA and Europe. Inclusion criteria: non cirrhotic treatment‐naive adult participants with chronic hepatitis C genotype 1. Exclusion criteria: not described.
Interventions	Experimental group 1: oral tegobuvir 40 mg twice daily for 48 weeks. Experimental group 2: oral tegobuvir 40 mg response‐guided for 24‐48 weeks. Control group: placebo. Co‐intervention: peg/RBV.
Outcomes	Safety assessment, pharmacokinetics, HCV RNA.
Notes	We emailed Lawitz and colleagues on 26 April 2016 for additional information on randomisation, blinding, missing data, protocol, complete trial, data, funding but reply not received yet.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not described
Allocation concealment (selection bias)	Unclear risk	Not described
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Described as placebo‐controlled, but it was not described how blinding was performed
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Described as placebo‐controlled, but it was not described how blinding was performed
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	More than 5% percent dropped out
Selective reporting (reporting bias)	Unclear risk	No protocol could be obtained
Vested‐interest bias	High risk	Several authors worked for Gilead Sciences
Other bias	Low risk	The trial appeared to be free of other components that could put it at risk of bias